{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:19:24Z","timestamp":1783091964160,"version":"3.54.6"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["CSC 202308430051"],"award-info":[{"award-number":["CSC 202308430051"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtha.2026.03.028","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:14:20Z","timestamp":1776726860000},"page":"2423-2435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-domain antibodies to reverse the effects of factor Xa inhibitors on coagulation tests"],"prefix":"10.1016","volume":"24","author":[{"given":"Junxiong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ischa","family":"Hoornstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Huskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Swieringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An K.","family":"Stroobants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Rijpma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Heylen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"de Laat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.03.028_bib1","article-title":"Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with liver disease: a systematic review and meta-analysis","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2026.03.028_bib2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jtha.2026.03.028_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2026.03.028_bib4","first-page":"504","article-title":"Bleeding and bruising: primary care evaluation","volume":"110","author":"Hughes","year":"2024","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jtha.2026.03.028_bib5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1373\/clinchem.2016.261248","article-title":"Biological variation of hemostasis variables in thrombosis and bleeding: consequences for performance specifications","volume":"62","author":"de Maat","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.jtha.2026.03.028_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005489","article-title":"Thrombin generation test as a useful tool for improving disease severity stratification in antiphospholipid syndrome","volume":"11","author":"Yelnik","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.jtha.2026.03.028_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial","volume":"9","author":"Freixa","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jtha.2026.03.028_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034412","article-title":"Temporal changes in long-term outcomes of venous thromboembolism from the warfarin era to the direct oral anticoagulant era","volume":"13","author":"Kaneda","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.03.028_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12959-023-00501-7","article-title":"The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review","volume":"21","author":"Frackiewicz","year":"2023","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2026.03.028_bib10","series-title":"Single domain antibodies: methods and protocols","first-page":"199","article-title":"Selection of VHHs under application conditions","author":"Dolk","year":"2012"},{"key":"10.1016\/j.jtha.2026.03.028_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jtha.2026.03.028_bib12","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.jtha.2024.05.032","article-title":"Global coagulation assays detect an early prothrombotic state in children with acute lymphoblastic leukemia","volume":"22","author":"Betticher","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib13","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/jth.14541","article-title":"Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: modeling and assessing interindividual variability","volume":"17","author":"Siguret","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cvr\/cvy272","article-title":"The prothrombotic state in atrial fibrillation: pathophysiological and management implications","volume":"115","author":"Khan","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2026.03.028_bib15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.immuni.2019.11.005","article-title":"Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure","volume":"51","author":"Yang","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jtha.2026.03.028_bib16","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1161\/STROKEAHA.118.023124","article-title":"Intrinsic coagulation pathway, history of headache, and risk of ischemic stroke","volume":"50","author":"van Os","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.03.028_bib17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtha.2024.02.008","article-title":"Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy","volume":"22","author":"Lind","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib18","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1055\/s-0038-1673684","article-title":"The clinical significance of fibrin monomers","volume":"118","author":"Refaai","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib19","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/dj4010005","article-title":"New direct oral anticoagulants (DOAC) and their use today","volume":"4","author":"Schwarb","year":"2016","journal-title":"Dent J (Basel)"},{"key":"10.1016\/j.jtha.2026.03.028_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.thromres.2024.04.005","article-title":"Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?","volume":"237","author":"Gendron","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.028_bib22","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.03.028_bib23","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-0041-1740180","article-title":"Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban","volume":"122","author":"Benz","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100100","article-title":"Procoagulant off-target effect of the direct oral anticoagulant reversal agent andexanet alfa","volume":"2","author":"Hoornstra","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2018.01.047","article-title":"Simple method for removing DOACs from plasma samples","volume":"163","author":"Exner","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.028_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ijlh.14020","article-title":"DOAC-stop can remove direct oral anticoagulants and allow analysis by global coagulation assays","volume":"45","author":"Wang","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.03.028_bib27","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jtha.2025.05.030","article-title":"Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialised coagulation assays and their removal by activated charcoal-based adsorbents","volume":"23","author":"Buckley","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib28","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.jtha.2025.05.032","article-title":"DOAC-Stop\u2122 reverses the anticoagulant effect of asundexian and milvexian","volume":"23","author":"Fitzpatrick","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.03.028_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ijlh.12950","article-title":"Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban","volume":"41","author":"Platton","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.03.028_bib30","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/ijlh.14321","article-title":"DOAC-Remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin","volume":"46","author":"Melicine","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2026.03.028_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2020.04.044","article-title":"Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays","volume":"192","author":"Monteyne","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.03.028_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2018.08.014","article-title":"Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay","volume":"170","author":"Kopatz","year":"2018","journal-title":"Throm Res"},{"key":"10.1016\/j.jtha.2026.03.028_bib33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/jcm13041042","article-title":"Simplified method for removing direct oral anticoagulant interference in mechanical coagulation test systems\u2014a proof of concept","volume":"13","author":"Exner","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.03.028_bib34","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1038\/s41467-024-51253-5","article-title":"Self-reporting photodynamic nanobody conjugate for precise and sustainable large-volume tumor treatment","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2026.03.028_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009492","article-title":"ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia\/macrophages","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:31:59Z","timestamp":1783089119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1538783626002643"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.03.028","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-domain antibodies to reverse the effects of factor Xa inhibitors on coagulation tests","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}